PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline…
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline…
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase…
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase…
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
Presentations highlight utility of this advanced hernia reinforcement material for robotic procedures MALVERN, Pa., March…
Presentations highlight utility of this advanced hernia reinforcement material for robotic procedures MALVERN, Pa., March…
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company…
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company…
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere…
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere…
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed…
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed…